1.
J Am Acad Dermatol
; 87(1): 1-18, 2022 07.
Article
in English
| MEDLINE
| ID: mdl-35202775
ABSTRACT
The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The first article in this continuing medical education series discusses new and emerging therapeutics for lupus erythematosus and Sjögren syndrome that target cells, intracellular signaling pathways, and cytokines.
Subject(s)
Biological Products , Connective Tissue Diseases , Lupus Erythematosus, Systemic , Sjogren's Syndrome , Connective Tissue Diseases/therapy , Humans , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Sjogren's Syndrome/complications , Sjogren's Syndrome/drug therapy
2.
J Am Acad Dermatol
; 85(3): 761-762, 2021 09.
Article
in English
| MEDLINE
| ID: mdl-31884089
